Sugar Maple Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Sugar Maple Asset Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$241K	Buy	58,060 +3,210	+6%	+$13K	0.15%	77
2025 Q4	$354K	Buy	54,850 +42,850	+357%	+$267K	0.24%	62
2025 Q3	$67.1K	Hold	12,000	–	–	0.05%	79
2025 Q2	$39.7K	Sell	12,000 -17,500	-59%	-$50.2K	0.03%	74
2025 Q1	$85.5K	Buy	+29,500	New	+$89.3K	0.07%	64

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sugar Maple Asset Management's AQST Position: Q1 2026 in Review

Sugar Maple Asset Management increased its Aquestive Therapeutics (AQST) stake by 5.9% in Q1 2026, buying an estimated $13K and bringing the position to 58,060 shares worth $241K. The position accounts for 0.15% of the portfolio, ranked #77.

Sugar Maple Asset Management first reported a position in AQST in Q1 2025 and has held it in 5 quarters since. The position peaked at $354K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

Sugar Maple Asset Management held 58,060 shares of Aquestive Therapeutics worth $241K as of Q1 2026.
Sugar Maple Asset Management bought 3,210 Aquestive Therapeutics shares in Q1 2026, an estimated $13K.
Aquestive Therapeutics made up 0.15% of Sugar Maple Asset Management's portfolio in Q1 2026, its #77 holding.
Sugar Maple Asset Management first reported a position in Aquestive Therapeutics in Q1 2025 and has held it in 5 quarters since.
Sugar Maple Asset Management's Aquestive Therapeutics position peaked at $354K in Q4 2025.
179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Sugar Maple Asset Management's 13F filing for Q1 2026, filed 21 Apr 2026.